Applications of Tert-Butanesulfinamide in Industrial Manufacturing

As a leading manufacturer of tert-butanesulfinamide, we provide this chiral auxiliary intermediate in bulk for key pharmaceutical and fine chemical production sectors. Below we outline industrial downstream scenarios where high-purity tert-butanesulfinamide plays an essential role—covering regulatory frameworks, typical loading, process integration, and corresponding finished products.

1. Chiral Amine Synthesis for Active Pharmaceutical Ingredients (APIs)

Pharmaceutical manufacturers utilize tert-butanesulfinamide extensively in asymmetric synthesis of non-racemic amines, forming a reliable intermediate for production of patented and generic APIs, including those for antihypertensive, anticancer, and antiviral therapies. The compound engages directly in auxiliary-enabled condensation, ensuring stereocontrol at scale. Stringent regulatory oversight applies at every stage, particularly regarding residual auxiliary removal and enantiomeric purity validation in intermediates and APIs.

Industry compliance standards

• ICH Q7 GMP for active pharmaceutical ingredients
• European Pharmacopoeia general texts (e.g., 2034, 2035) on chiral purity
• US FDA cGMP 21 CFR Part 211
• Chinese Pharmacopoeia (ChP) Appendix XII G

Typical usage ratio

• 1.0–1.2 molar equivalents per ketone or aldehyde substrate, adjusted for desired diastereoselectivity and downstream removal efficiency

Downstream process integration

• Introduced at the condensation step with carbonyl precursors, forming tert-butanesulfinyl imines/hemiaminals before chiral addition or reduction reactions
• Removed post-reaction via acidic hydrolysis or reductive cleavage after purification of the targeted amine intermediate

Final product types

• Chiral amine-based intermediates for antihypertensive APIs
• Sitagliptin and similar DPP-4 inhibitor actives
• Enantiopure intermediates for oncology drug substances
• Building blocks for new chemical entity (NCE) development

2. Fine Chemical Synthesis of Agrochemical Intermediates

Large-scale agrochemical syntheses incorporate tert-butanesulfinamide in stereocontrolled routes, particularly when preparing optically active intermediates for pesticides, herbicides, and fungicides. The compound boosts yields of single-enantiomer precursors, supporting green chemistry initiatives by reducing the need for downstream resolution processes. Compliance with sector-specific safety, environmental, and product testing protocols directly governs raw material application.

Industry compliance standards

• REACH (EC 1907/2006) for raw material registration and safe use
• ISO 9001:2015 for quality management in chemical synthesis
• OECD Test Guidelines for environmental safety (e.g., TG 301)
• Chinese National Agrochemical Registration (GB/T 1601-2017)

Typical usage ratio

• 1.05–1.1 molar equivalents relative to chiral substrate, dictated by process selectivity goals and downstream environmental performance

Downstream process integration

• Applied at the stage of constructing chiral amines or amino acid derivatives; reacts with aldehyde/ketone to introduce chiral center
• Auxiliary removed by in situ hydrolysis after isolation of the chiral intermediate, minimizing waste

Final product types

• Single-isomer amine intermediates for pyrethroid insecticides
• Enantiopure intermediates for triazole fungicides
• Aromatic amine derivatives for novel herbicidal agents

3. Manufacture of Fine Chemical Building Blocks for Specialty Materials

Manufacturers of advanced specialty chemicals use tert-butanesulfinamide to access enantioenriched amines and related functional monomers essential in electronic materials, chiral catalysts, and certain performance polymers. Adding this chiral auxiliary at the proper step is crucial for maintaining material attributes such as selectivity and reactivity. All production follows material-specific certifications and industry standards, particularly regarding trace metals and organic impurities.

Industry compliance standards

• ISO 14001:2015 for environmental management in fine chemical plants
• RoHS 2 (Directive 2011/65/EU) for material safety in electronics
• Semiconductor Industry Association (SIA) supplier quality guidelines
• REACH Annex XVII limited substance lists

Typical usage ratio

• 0.9–1.2 equivalents depending upon the electronic effect of target molecule and polymerization requirements

Downstream process integration

• Dosed into condensation or coupling reactions to form chiral amines used as building blocks in downstream functionalization (e.g., as monomers or ligands)
• Auxiliary cleavage and removal performed after crystallization or column purification

Final product types

• Chiral ligands for asymmetric catalysis
• Enantiopure monomers for functional polymers
• Chiral auxiliaries for electronic and optical material synthesis

4. Custom Synthesis for Medicinal Chemistry Research

Contract research and custom synthesis organizations purchase tert-butanesulfinamide in bulk for asymmetric library construction and structure-activity relationship (SAR) development. The product allows rapid access to a diverse range of nonracemic amines and analogs, fulfilling strict control criteria demanded by modern medicinal chemistry labs. When supplied for research use, compliance aligns with chemical handling, documentation, and laboratory QA systems.

Industry compliance standards

• ISO/IEC 17025 for quality of calibration and testing laboratories
• Good Laboratory Practice (GLP) for discovery research
• IUPAC nomenclature and reporting guidelines
• GHS compliant SDS for chemical safety

Typical usage ratio

• Variable; typically 1.0–1.5 equivalents depending on substrate scope and library scale-up requirements

Downstream process integration

• Employed in primary condensation or reductive amination when generating focused amine libraries
• Auxiliary removed by acidolysis or redox, followed by isolation of pure amine products for screening

Final product types

• Screening libraries of chiral amines for lead optimization
• Analytical reference standards for R&D
• Building blocks for patentable pharmaceutical candidates